1700 Montgomery Street
About Spruce BiosciencesSpruce Biosciences is a clinical-stage biopharmaceutical based in San Francisco, California. Our mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis (the “stress pathway”).
CEO: Alexis Howerton
Please click here for Spruce Biosciences job opportunities.
Please click here for clinical trial information.
7 articles with Spruce Biosciences
Spruce Biosciences Achieves Proof of Concept in Phase 2 Study of Tildacerfont in Congenital Adrenal Hyperplasia
Well-tolerated and safe, tildacerfont holds potential as a treatment for patients with congenital adrenal hyperplasia, a rare endocrine disorder
Moriarty brings 18 years of clinical industry experience to Spruce to advance SPR001, the company's lead program for congenital adrenal hyperplasia (CAH), through Phase 2 clinical trials and expand into additional indications
Spruce Biosciences Launches Natural History Study for Congenital Adrenal Hyperplasia in Time for World Rare Disease Day
Study Aims to Support Patients, Improve Care and Accelerate Research for Rare Disorder by Putting Power in Patients' Hands
Spruce Biosciences Receives EMA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia
Earlier this month, Spruce also received orphan drug designation for SPR001 from the FDA.
Spruce Biosciences Receives FDA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia
Spruce Biosciences today announced that the FDA has granted orphan drug designation for SPR001 for the treatment of congenital adrenal hyperplasia.
Previously, Ms. Simpson was Group Vice President of Regulatory Affairs at BioMarin, and has 22 years of experience in the industry.
Spruce Biosciences Provides Corporate Update On Series A Venture Financing, Leadership Team And Lead Clinical Program